Anti-tianeptin antibody or antigen binding fragment thereof and application thereof
By developing the anti-Tianeptine monoclonal antibody anti-Tianeptine-mab1, the problems of speed, sensitivity, and accuracy in on-site detection of tianeptine have been solved, reducing the false positive rate and dependence on purchased raw materials, and improving the sensitivity of the test and the competitiveness of the product.
Patent Information
- Application Number
- CN202411189874.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-28
- Publication Date
- 2024-11-22
AI Technical Summary
Existing technologies are insufficient for rapid, sensitive, and accurate on-site testing of tianeptine, and there is a risk of abuse and withdrawal symptoms, thus lacking effective testing methods.
A highly specific anti-Tianeptine monoclonal antibody, anti-Tianeptine-mab1, was developed. A tianeptine detection kit was prepared using an immunological method. The high specificity of this antibody enhances the sensitivity and accuracy of the detection.
This has enabled rapid diagnosis of tianeptine, reduced the false positive rate, improved the sensitivity of the test and the competitiveness of the product, and reduced dependence on purchased raw materials.
Smart Images

Figure CN118994407A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to an anti-tianeptine antibody or an antigen-binding fragment thereof and an application thereof. Background Art
[0002] The following statements merely provide background information related to the present disclosure and do not necessarily constitute prior art.
[0003] Tianeptine is an antidepressant, a new tricyclic drug, and an antidepressant. Its molecular structure is shown in formula (I).
[0004]
[0005] Tianeptine is mainly used clinically to treat the 5-HT system of depression and has an antidepressant effect. Domestic and foreign studies have found that tianeptine not only has a good antidepressant effect, but also has significantly fewer side effects than traditional tricyclic antidepressants. In the absence of the cardiovascular system, it has almost no adverse effects, no damage to the liver, kidney function and blood energy, and no sedative effect. Tianeptine can not only treat depression, but also prevent recurrence by long-term use, and has fewer adverse reactions in the treatment of depression symptoms after chronic alcohol poisoning, alcohol withdrawal, and depressive neurosis. Tianeptine is suitable for clinical treatment of patients with depression who have good tolerance and high dependence. In addition, its effect is similar to that of opioids, with dull pain and euphoria at higher doses.
[0006] Tianeptine is a controversial drug that is available as a dietary supplement under six common street names, including Tia, Tianna, Cas-stationdope, Zaza, TD red, and Pegasus. Current research suggests that people with a history of opioid use disorder or dependence are most at risk for misusing tianeptine. Some people have used tianeptine as an alternative to opioids to self-treat anxiety or depression.
[0007] Medical reports indicate that adverse events may occur when tianeptine is taken at doses higher than those prescribed in the countries where it has been approved. Some people have difficulty stopping tianeptine and experience withdrawal symptoms. Symptoms of abuse and withdrawal of tianeptine are similar to those of opioid toxicity and withdrawal, including: irritability, drowsiness, confusion, sweating, rapid heartbeat, high blood pressure, nausea, vomiting, slowed or stopped breathing, coma, and death. Supplements containing tianeptine are highly addictive, and common side effects include: abdominal pain, rapid heartbeat, stomach rebound, high blood pressure, drowsiness, confusion, irritability, difficulty breathing, constipation, headache, and even life-threatening.
[0008] At present, the detection of tianeptine mainly includes liquid chromatography-mass spectrometry (HPLC-MS), gas chromatography-mass spectrometry (GC-MS), spectral analysis, capillary electrophoresis and electrochemical analysis. Most of them are limited to laboratory detection, and few are directly used for on-site detection. The realization of on-site detection of tianeptine will be of great significance to the medical monitoring of tianeptine blood concentration and the detection of criminal cases such as suicide and poisoning. Therefore, it is necessary to establish a fast, sensitive and accurate detection technology.
[0009] In order to solve the problem of large-scale application on site, immunological methods have attracted much attention due to their fast detection speed, low cost, high throughput, and some immunological detection methods (colloidal gold paper chromatography) are also simple to operate and do not require additional equipment. Therefore, the development of excellent antibodies for tianeptine diagnosis has become the key to determining the application prospects of immunological methods.
[0010] In view of this, the present invention is proposed. Summary of the invention
[0011] The object of the present invention is to provide an antibody or an antigen-binding fragment thereof that can specifically bind to tianeptine. Based on the antibody or the antigen-binding fragment thereof, the present invention also provides the application of the antibody or the antigen-binding fragment thereof in a tianeptine detection method and product.
[0012] In order to solve the above technical problems, the present invention particularly adopts the following technical solutions:
[0013] In a first aspect, an anti-tianeptine antibody or an antigen-binding fragment thereof is provided, wherein the antibody or the antigen-binding fragment thereof comprises the complementarity determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region, and the complementarity determining regions LCDR1, LCDR2 and LCDR3 of the light chain variable region;
[0014] The HCDR1, HCDR2 and HCDR3 include amino acid sequences consistent with HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO.1; the LCDR1, LCDR2 and LCDR3 include amino acid sequences consistent with LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO.2.
[0015] In a second aspect, a biomaterial is also provided, wherein the biomaterial is selected from any one of (i) to (iii):
[0016] (i) a polynucleotide encoding the nucleotide sequence of the anti-tianeptine antibody or antigen-binding fragment thereof according to the first aspect.
[0017] (ii) a vector carrying the polynucleotide described in (i).
[0018] (iii) a cell, wherein the cell carries the polynucleotide described in (i), or contains the vector described in (ii), or expresses the anti-tianeptine antibody or its antigen-binding fragment.
[0019] In a third aspect, a composition containing an antibody is also provided, wherein the composition containing an antibody comprises the following (I) and (II) connected or separately packaged:
[0020] (I) The anti-tianeptine antibody or antigen-binding fragment thereof according to the first aspect.
[0021] (II) Label and / or solid phase carrier.
[0022] In a fourth aspect, there is provided the use of the anti-tianeptine antibody or antigen-binding fragment thereof described in the first aspect, or the biomaterial described in the second aspect, or the antibody-containing composition described in the third aspect in detecting tianeptine for non-diagnostic and therapeutic purposes, or in preparing a product for detecting tianeptine.
[0023] In a fifth aspect, a kit for detecting tianeptine is provided, the kit comprising the anti-tianeptine antibody or antigen-binding fragment thereof according to the first aspect, or the antibody-containing composition according to the third aspect.
[0024] Compared with the prior art, the present invention has the following beneficial effects:
[0025] The present invention uses tianeptine to immunize Balb / c mice, obtains mouse spleen cells and fuses them with myeloma cells, obtains highly specific hybridoma cells through specific high-throughput screening, obtains a large amount of mouse ascites through culture and re-immunization, and then obtains high-purity, high-sensitivity and high-specificity anti-tianeptine monoclonal antibody anti-Tianeptine-mab1 through multi-step separation and purification, which provides the required raw materials for developing immune test strips for detecting tianeptine. The anti-tianeptine antibody or its antigen-binding fragment of the present invention has been verified to have good specific binding ability, and can provide a stable and reliable source of raw materials for the method for detecting tianeptine based on immunological principles, reduce the dependence of the product on purchased raw materials, and reduce product costs. At the same time, the detection rate and sensitivity of tianeptine rapid diagnosis products such as gold label test strips, ELISA kits, etc. are improved, the false positive rate is reduced, and the competitiveness of self-produced products is improved. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] In order to more clearly illustrate the specific implementation methods of the present invention or the technical solutions in the prior art, the drawings required for use in the specific implementation methods or the description of the prior art will be briefly introduced below. Obviously, the drawings described below are some implementation methods of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0027] Figure 1 The results are shown in Example 3 for the negative control (a) and the 750 ng / ml Tianeptine standard (b and c) tested by the colloidal gold test strip coated with antibody #6. DETAILED DESCRIPTION
[0028] The technical solution of the present invention will be clearly and completely described below in conjunction with the embodiments. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0029] Generally, the nomenclature and its technology used in conjunction with cell and tissue culture, molecular biology, immunology, microbiology, genetics, and protein and nucleic acid chemistry and hybridization described herein are those well-known and commonly used in the art. Unless otherwise indicated, the methods and techniques of the present invention are generally carried out according to conventional methods as well-known in the art, and as described in various general and more specific references, which are cited and discussed throughout this specification. Enzymatic reactions and purification techniques are carried out according to the manufacturer's specifications, as generally achieved in the art, or as described herein. The nomenclature and its laboratory procedures and technology used in conjunction with analytical chemistry, synthetic organic chemistry, and medical and pharmaceutical chemistry described herein are those well-known and commonly used in the art.
[0030] Antibodies herein generally refer to all proteins and protein fragments that contain a complementary determining region (CDR region). The terms "antibody" and "full-length antibody" include polyclonal antibodies and monoclonal antibodies. In addition, the term "antibody" includes naturally occurring antibodies as well as non-naturally occurring antibodies, including, for example, chimeric, bifunctional and humanized antibodies, and related synthetic isoforms. Non-naturally occurring antibodies are also referred to herein as "recombinant antibodies," and the term "antibody" can be used interchangeably with "immunoglobulin."
[0031] Antigen binding fragments are fragments that contain part or all of the antibody CDRs, which lack at least some of the amino acids present in the full-length chain but are still able to specifically bind to the antigen. Such fragments are biologically active because they bind to the target antigen and can compete with other antigen binding molecules (including intact antibodies) for binding to a given epitope. Such fragments are selected from, but not limited to, F(ab')2, Fab', Fab, Fv (composed of VH and VL), ScFv (single-chain antibody, VH and VL are connected by a connecting peptide), dsFv (disulfide stabilized Fv fragments, dsFv), bispecific antibodies, nanobodies, and any one of the minimum recognition units of antibodies. In addition to the above functional fragments, any fragments with increased half-life are also included.
[0032] The "variable region" or "variable domain" of an antibody refers to the domain at the amino terminus of the heavy chain or light chain of the antibody that recognizes and binds to the antigen. The composition and arrangement of the amino acids in this segment determine the specificity of the antibody in recognizing the antigen. The heavy chain variable domain can be referred to as "VH". The variable domain of the light chain can be referred to as "VL". These domains are usually the most variable parts of the antibody and contain the antigen binding site. The variable regions of the heavy and light chains are each composed of three complementarity-determining regions (CDR) (also called hypervariable regions) connected by four framework regions (FR). The extent of the framework region and CDR has been precisely defined, for example, in Kabat (see Sequences of Proteins of Immunological Interest, E. Kabat et al.) and Chothia. Any CDR determination method well known in the art, including a combination of methods, can identify the CDRs of the variable domain. The CDRs in each chain are held together closely by FRs to form the variable region. Generally, the variable regions VL / VH of the heavy and light chains can be obtained by arranging and connecting the following numbered CDRs and FRs in the following combinations: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
[0033] The term "constant region" or "constant domain" of an antibody refers to the constant region of an antibody light chain or the constant region of an antibody heavy chain, either alone or in combination. The heavy chain of an antibody has one variable domain (VH), followed by a number of constant domains or regions, such as one or more of a hinge, CH1, CH2, CH3, and CH4, the CH1 domain being adjacent to the VH domain and at the amino terminus of the hinge region of the antibody heavy chain, and not forming part of the Fc region of the antibody; the hinge region includes the portion of the heavy chain molecule that connects the CH1 domain to the CH2 domain; the N-terminus of CH2 is usually the CH3 domain, which usually forms the C-terminal portion of the antibody, and in some antibody types, such as IgM and IgE, the constant region also includes a CH4 domain. The constant region of an antibody can be derived from IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE, and IgD, as well as subclasses and mutant forms of the constant regions thereof.
[0034] The present invention does not limit the method of obtaining the anti-tianeptine antibody or antigen-binding fragment. In some optional embodiments, the polynucleotide encoding the anti-tianeptine antibody or antigen-binding fragment is connected to the vector and then expressed in the cell to obtain the corresponding antibody. The above-mentioned vector can be introduced into eukaryotic cells, especially mammalian cells, to construct and obtain the anti-tianeptine antibody or antigen-binding fragment that can express it. In other optional embodiments, the anti-tianeptine antibody or antigen-binding fragment can also be obtained by recombinant genetics techniques known to those skilled in the art or by peptide synthesis, such as automatic peptide synthesizers (e.g., automatic peptide synthesizers sold by Applied BioSystems, etc.); the antigen-binding fragment can also be optionally produced by enzymatic cleavage of antigen-binding molecules (including intact antibodies), such as pepsin or papain cleavage; or chemical cleavage, such as chemical reduction to split disulfide bonds to obtain the above-mentioned antigen-binding fragment.
[0035] The terms "specific recognition", "selective binding", "selectively binds" and "specifically binds" or similar expressions refer to the binding of an antibody or its antigen-binding fragment to a predetermined epitope on an antigen. -5 M, for example, less than about 10 -5 M, 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M or 10 -10 The Kd value of an antibody can be determined using methods well established in the art. Other standard assays for evaluating the binding ability of a ligand such as an antibody to a target are known in the art and include, for example, ELISA, Western blot, RIA, and flow cytometry analysis.
[0036] The term "polynucleotide" herein refers to a polymer form of nucleotides of any length, including ribonucleotides and / or deoxyribonucleotides. Examples of polynucleotides include, but are not limited to, single-stranded, double-stranded or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or polymers containing purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural or derived nucleotide bases. The polynucleotide encodes the above-mentioned anti-tianeptine antibody or antigen-binding fragment, and the encoding is optionally encoding a sense strand or an antisense strand. The polynucleotide can be naturally occurring, synthetic, recombinant, or any combination thereof. The terms "polynucleotide" and "nucleic acid" are used interchangeably herein.
[0037] The term "vector" herein refers to a nucleic acid delivery vehicle into which a polynucleotide can be inserted. When a vector can express a protein encoded by the inserted polynucleotide, the vector is called an expression vector. The vector can be introduced into a host cell by transformation, transduction or transfection so that the genetic material elements it carries are expressed in the host cell.
[0038] The vector is well known to those skilled in the art, including but not limited to: plasmid; phagemid; cosmid; artificial chromosome, such as yeast artificial chromosome (YAC), bacterial artificial chromosome (BAC) or P1-derived artificial chromosome (PAC); bacteriophage such as lambda phage or M13 phage and animal virus, etc. Animal viruses that can be used as vectors include but are not limited to retrovirus (including lentivirus), adenovirus, adeno-associated virus, herpes virus (such as herpes simplex virus), poxvirus, baculovirus, papillomavirus, papillomavirus. In some embodiments, the vector of the present invention contains regulatory elements commonly used in genetic engineering, such as enhancers, promoters, internal ribosome entry sites (IRES) and other expression control elements (such as transcription termination signals, or polyadenylation signals and poly-U sequences, etc.).
[0039] As used herein, the expressions "cell", "cell line" and "cell culture" are used interchangeably, and all such designations include progeny. Progeny may not necessarily be identical to the original cell due to natural, accidental or deliberate mutation, and may differ from the original cell in morphology and / or in genomic DNA. "Transformants" and "transformed cells" include the primary subject cell and cultures derived therefrom.
[0040] In a first aspect, an anti-tianeptine antibody or an antigen-binding fragment thereof is provided, wherein the antibody or the antigen-binding fragment thereof comprises the complementarity determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region, and the complementarity determining regions LCDR1, LCDR2 and LCDR3 of the light chain variable region;
[0041] The HCDR1, HCDR2 and HCDR3 include amino acid sequences consistent with HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO.1; the LCDR1, LCDR2 and LCDR3 include amino acid sequences consistent with LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO.2.
[0042] It is understood that other regions except the CDR region in the variable region shown in SEQ ID NO.1 and 2 are not used to limit the anti-tianeptine antibody or antigen-binding fragment thereof provided by the present invention. For example, if the antibody or antigen-binding fragment thereof provided in the present application contains a framework region, it may be different from the framework region in the variable region shown in SEQ ID NO.1 and 2. The CDR region in the variable region shown in SEQ ID NO.1 and 2 can be divided according to an optional method known in the art. Optionally, the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 of the variable region is defined by any one of the systems of Kabat, Chothia, IMGT, ABM or Contact or a combination of multiple definition systems. Taking the definition of Kabat, Chothia, IMGT, ABM or Contact as examples, the amino acid sequences of HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO.1 are shown in Table 1, and the amino acid sequences of LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO.2 are shown in Table 2:
[0043] Table 1
[0044]
[0045] Table 2
[0046]
[0047] In an optional embodiment, the heavy chain variable region further comprises a framework region, and / or the light chain variable region further comprises a framework region. The species origin of the framework region includes, but is not limited to, one or more of rabbit, cattle, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, camel, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock, human and their mutants.
[0048] In an optional embodiment, the heavy chain variable region of the antibody or antigen-binding fragment thereof is shown as SEQ ID NO.1, and the light chain variable region is shown as SEQ ID NO.2.
[0049] In an optional embodiment, the antigen-binding fragment includes one or more of F(ab')2, Fab', Fab, Fv, scFv, dsFv and the minimum recognition unit of an antibody.
[0050] In an alternative embodiment, the antibody or antigen-binding fragment thereof comprises a portion or all of the sequence of the constant region.
[0051] In an optional embodiment, the constant region sequence is selected from the sequence of a partial or complete constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD, and the IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD include their subclasses and mutant forms.
[0052] In an optional embodiment, the species origin of the constant region is one or more of rabbit, cow, horse, dairy cow, pig, sheep, goat, rat, mouse, dog, cat, camel, donkey, deer, mink, chicken, duck, goose, turkey, fighting cock, human and their mutants.
[0053] In an optional embodiment, the antibody comprises a heavy chain constant region and a light chain constant region, is a full-length antibody, the light chain of the antibody is a κ chain, and the antibody is an IgG antibody. In an optional embodiment, the full-length antibody is a mouse antibody.
[0054] In a second aspect, a biomaterial is also provided, wherein the biomaterial is selected from any one of (i) to (iii):
[0055] (i) a polynucleotide encoding the nucleotide sequence of the anti-tianeptine antibody or antigen-binding fragment thereof according to the first aspect.
[0056] In an optional embodiment, the polynucleotide contains a nucleotide sequence as shown in SEQ ID NO.3, which encodes the heavy chain variable region shown in SEQ ID NO.1.
[0057] In an optional embodiment, the polynucleotide contains a nucleotide sequence as shown in SEQ ID NO.4, which encodes the light chain variable region shown in SEQ ID NO.2.
[0058] (ii) a vector carrying the polynucleotide described in (i).
[0059] (iii) a cell, wherein the cell carries the polynucleotide described in (i) above, or contains the vector described in (ii) above, or expresses the anti-tianeptine antibody or its antigen-binding fragment.
[0060] In a third aspect, a composition containing an antibody is also provided, wherein the composition containing an antibody comprises the following (I) and (II) connected or separately packaged:
[0061] (I) The anti-tianeptine antibody or antigen-binding fragment thereof according to the first aspect.
[0062] (II) Label and / or solid phase carrier.
[0063] The connection includes physical connection and / or chemical connection, for example, it can be but not limited to connecting the anti-tianeptine antibody or antigen-binding fragment thereof described in the first aspect with the marker and / or solid phase carrier through chemical bonds or adsorption.
[0064] In an optional embodiment, the marker includes but is not limited to one or more of enzymes, fluorescent molecule markers, fluorescent microspheres, colored microspheres, latex microspheres, colloidal gold, colloidal selenium, colloidal silver, colloidal carbon, quantum dots, biotin, streptavidin, radionuclides, radiocontrast agents, paramagnetic ions, metals and photosensitizers.
[0065] In an optional embodiment, the solid phase carrier includes but is not limited to microtubes, columns, microparticles, nitrocellulose membranes, chromatography matrices or lateral flow devices; more specifically, for example, it can be but is not limited to enzyme-labeled wells, immunochromatographic test strips or magnetic beads.
[0066] In a fourth aspect, there is provided a use of the anti-tianeptine antibody or antigen-binding fragment thereof described in the first aspect, or the biomaterial described in the second aspect, or the antibody-containing composition described in the third aspect in detecting tianeptine for non-diagnostic and therapeutic purposes, or in preparing a product for detecting tianeptine.
[0067] In the fifth aspect, a kit for detecting tianeptine is also provided, the kit comprising the anti-tianeptine antibody or antigen-binding fragment thereof of the first aspect, or the composition containing the antibody of the third aspect. The kit comprises one or more reagents, and when the kit comprises one reagent, the kit may be equivalent to the reagent.
[0068] In an optional embodiment, the kit includes an immunochromatographic detection kit, an ELISA detection kit, an immunomagnetic particle detection kit, an immunofluorescence detection kit or an immunoblot detection kit.
[0069] In an optional embodiment, the kit further contains reagents and / or consumables for detection, including but not limited to one or more of primers, probes, buffers, dyes, diluents, washing solutions, color developing solutions, lysates, negative controls, positive controls, and blank controls; consumables include but are not limited to solid phase carriers, such as magnetic beads, enzyme-labeled wells, or nitrocellulose membranes, etc. Those skilled in the art can select the reagent composition of the kit according to the specific detection method, and the present invention does not limit this.
[0070] In an optional embodiment, the kit includes an immunochromatographic test paper, which is a competitive immunochromatographic test paper. The competitive immunochromatographic test paper is coated with the antibody or antigen-binding fragment thereof in any of the above embodiments, and is used to capture tianeptine in the sample to be tested.
[0071] In an optional embodiment, the detection line of the immunochromatographic test paper is coated with tianeptine hapten, and the binding pad is coated with the anti-tianeptine antibody or its antigen-binding fragment labeled with a marker. It is understandable that the immunochromatographic test paper has a conventional immunochromatographic test paper structure known in the art, and an exemplary immunochromatographic test paper structure includes a sample pad, a binding pad and a detection pad along the sample flow direction, and the detection pad is provided with a detection line and a quality control line. The quality control line is coated with an antibody that specifically binds to the anti-tianeptine antibody or its antigen-binding fragment; when the sample contains tianeptine, the tianeptine in the sample and the tianeptine hapten coated on the detection line and the anti-tianeptine antibody or its antigen-binding fragment on the binding pad are competitively bound, and the higher the tianeptine content in the sample, the fewer anti-tianeptine antibodies or their antigen-binding fragments that bind to the tianeptine hapten on the detection line, and the fewer detectable signals on the detection line. The anti-tianeptine antibody or antigen-binding fragment thereof labeled with a marker flows through the quality control line and is captured by the antibody coated on the quality control line, and a measurable signal appears, indicating that the immunochromatographic test paper is usable.
[0072] In an optional embodiment, the immunochromatographic test paper is coated with an antibody that binds to tianeptine and is labeled with a marker, and the amino acid sequence of the heavy chain variable region of the antibody that binds to tianeptine is shown in SEQ ID NO.1, and the amino acid sequence of the light chain variable region is shown in SEQ ID NO.2.
[0073] In an optional embodiment, the anti-tianeptine antibody or antigen-binding fragment thereof coated on the conjugate pad is labeled with colloidal gold.
[0074] The present invention is further described below by means of specific examples. However, it should be understood that these examples are only used for more detailed description and should not be construed as limiting the present invention in any form.
[0075] Example 1 Preparation of Tianeptine-BGG Hapten
[0076] 1. Take 50 mg of tianeptine product 1 and dissolve it in 1 ml of DMF (N,N-dimethylformamide) to prepare a 50 mg / ml solution, and add NHS (4-vinylsulfonylbenzoic acid) and EDC (1-(3-dimethylaminopropyl)-3-ethylcarbodiimide) to activate and react at room temperature overnight. The molar ratio of product 1 to NHS and EDC is 1:1.2~1.5:1.2~1.5.
[0077] 2. Weigh 100 mg of BGG (bovine serum gamma globulin) and dissolve it in 10 ml of PBS buffer to prepare a 10 mg / ml solution. Slowly add the activated small molecules to the protein and react for 8 hours.
[0078] 3. Place the coupled antigen into a dialysis bag, change the solution every two hours, for a total of more than six times, collect samples, measure the concentration using Lowry, and obtain the synthetic antigen tianeptine-BGG.
[0079] The experimental mice were immunized in stages with chemically synthesized tianeptine hapten.
[0080] Example 2 Preparation of monoclonal antibody anti-Tianeptine-mab1
[0081] 1. Preparation of monoclonal antibody anti-Tianeptine-mab1:
[0082] Healthy female Balb / c mice aged 6 to 8 weeks were selected and immunized according to a pre-specified immunization protocol. As an immunogen, BALB / c mice were immunized, spleen lymphocytes of successfully immunized mice were extracted, and lymphocytes were fused with mouse myeloma cells SP2 / 0 by cell fusion technology. After two rounds of subclone screening, hybridoma cell lines that stably secreted monoclonal antibodies against tianeptine were obtained, thereby obtaining monoclonal antibodies against tianeptine.
[0083] The experimental mice were immunized in stages with chemically synthesized tianeptine hapten.
[0084] The specific steps of animal immunization experiments include:
[0085] 1. Balb / c mice with the same mean body weight and age were randomly divided into two groups: the group with aluminum adjuvant (aluminum hydroxide adjuvant) and the group without aluminum adjuvant.
[0086] 2. Before the experiment, the pre-immune serum of each mouse was collected (pre-immune serum was collected on the fifth day, blood was collected through the eyeball, and an appropriate amount of blood was collected to ensure the normal state of the mice), and the collected serum was stored at -80°C.
[0087] 3. Preparation of the aluminum adjuvant (aluminum hydroxide adjuvant) group: Before immunization, each antigen was diluted to the corresponding dose (75 μg / mouse) in 75 μL PBS, and mixed with alum adjuvant (1 mg / mouse), according to the volume of antigen: adjuvant = 3:1 (i.e., 25 μL adjuvant was added to 75 μL immunogen diluent); the adjuvant was shaken before use, and the injection adjuvant (25 μL) was slowly added to the immunogen solution; after the adjuvant and the immunogen diluent were fully mixed, the two were fully mixed for 30 minutes. The adjuvant effectively adsorbed the antigen; the subsequent operation was carried out according to the immunization animal experiment.
[0088] 4. Group without aluminum adjuvant: The antigens were diluted in 100 μL PBS to the corresponding doses in the above table (75 μg / mouse), and 100 μL of immunogen was added. The subsequent operation was carried out according to the animal immunization experiment.
[0089] 5. Subcutaneous injection at intervals of 2 weeks: The experiment was designed for 4 immunizations, but blood was collected from the eyeballs 4 days after each immunization, and part of the mouse supernatant was obtained by centrifugation. The serum titer was first tested. 7 days after the last immunization, blood was collected from the heart to obtain the maximum amount of blood, which was centrifuged to obtain the supernatant and stored at -80°C.
[0090] 6. Detect serum titer.
[0091] (1) Two mice were immunized, and the mice were numbered A0 and A1. After three immunizations, the serum titer was tested. The test data are shown in Table 3 below, and the test method is as follows:
[0092] The antigen competition test was performed using tianeptine hapten and tianeptine small molecule, respectively. The tianeptine hapten was used as the coating antigen for indirect ELISA and competitive ELISA to detect the titer of the immune mouse serum. 50 μL of the coating antigen diluted with the coating solution was added to each well of the indirect ELISA enzyme labeling plate at 1 μg / ml. After coating overnight at 4°C, the plate was washed 3 times with a washing solution (PBST) (the same below). 200 μL of blocking solution (5% skim milk powder) was added to each well, and the plate was placed in a 37°C incubator for 2 hours. After washing, 50 μL of diluted serum was added to each well, and the plate was reacted in a 37°C incubator for 30 minutes. After washing, 50 μL of goat anti-mouse IgG-HRP solution was added, and the plate was reacted in a 37°C incubator for 30 minutes. After washing, 100 μL of substrate solution was added, and the plate was colorized in a 37°C incubator for 10 minutes in the dark. Finally, 50 μL of 2 mol / L H2SO4 was added to terminate the reaction, and the A450 value was read on an enzyme labeling instrument. The titers of orbital blood of three mice after three immunizations were all >312500.
[0093] The process of indirect competitive ELISA is mostly the same as that of indirect ELISA, except that after blocking with blocking solution and washing the ELISA plate, 50 μL of diluted 200 ng / mL small molecule tianeptine standard solution is added, and then 50 μL of diluted serum antibody is added to make the final concentration of the small molecule reach 100 ng / mL. The rest of the steps are the same. In the competition test of 100 ng / ml small molecule tianeptine, more than 80% can be achieved at 1:62500, and fusion can be arranged.
[0094] Table 3: Serum titer test data
[0095]
[0096] The immune spleen cells were fused with myeloma cell line SP2 / 0 cells, and the fused cells were screened by HAT selection medium (HAT selection medium contains hypoxanthine, aminopterin and thymidine), and the fused cells were subjected to ELISA positive screening and subcloning; the screened positive monoclonal antibody was purified from ascites using Protein A / G antibody purification column, and the ELISA titer of the purified antibody was >1:128,000, and the purity was >90%.
[0097] 2. Enzyme-linked immunosorbent assay (ELISA) was used to detect and identify the binding activity of tianeptine.
[0098] 1. IgG antibody titer detection method
[0099] (1) Bottom plate coating: Dilute the antigen to be used to 3 μg / ml with coating diluent, add 100 μL of the prepared coating solution to each well, and place in a 4°C refrigerator for 24 h.
[0100] (2) After 24 hours, take the wells out of the refrigerator and place them at 37°C for 30 minutes. Then discard the liquid in the wells and wash the wells three times with washing solution, each time for 3 minutes.
[0101] (3) Blocking the enzyme-labeled reaction wells: Add 200 μL of 5% calf serum to each well and block at 37°C for 90 min. After blocking, wash the well three times with washing solution, each time for 3 min.
[0102] (4) Adding the sample to be tested: dilute the sample according to the required ratio, add the diluted sample to the enzyme-labeled reaction well, 100 μL per well, incubate at 37°C for 90 min; wash the well three times with washing solution, each time for 3 min.
[0103] (5) Add enzyme-labeled antibody: Add secondary antibody of appropriate concentration according to the instructions; incubate at 37°C for 90 min, add 100 μL per well and wash as before.
[0104] (6) Add substrate solution: 100 μL of substrate is added to each well and incubate at 37°C in the dark for 15 to 30 min.
[0105] (7) Termination of reaction: Add 50 μL of stop solution to each well to terminate the reaction and measure the experimental results within 20 min.
[0106] 3. Detect the binding activity of monoclonal antibodies to tianeptine.
[0107] 1. Cell fusion and clone screening data
[0108] The mice were numbered A0 and A1, and four rounds of fusion were completed.
[0109] A total of 30 positive wells were selected from the A0 mouse fusion screening, and subcloning was performed, and 8 cell lines were finally obtained. In the first subclone screening, 12 positive clones with OD450 values > 2.5 were selected for titer detection by multiple dilution. A second subclone screening was performed, and 4 positive cell lines were obtained. 8 cell lines were selected for the third subcloning, and 4 positive cell lines were obtained.
[0110] A1 mouse fusion screening picked out 56 positive wells, and finally completed 10 cell lines. In the first subclone screening, a total of 32 positive clones with OD450 values > 2.5 were selected. A second subclone screening was performed, and 4 cell lines were completed. 18 cell lines were selected for the third subcloning, and 6 cell lines were completed. 5 cell lines were selected for the fourth subcloning, and 3 cell lines were completed.
[0111] A total of 18 complete cell lines were obtained after the second cell fusion.
[0112] 2. Ascites preparation and testing data
[0113] One F1 mouse was used for each complete cell line. Two cell lines did not produce ascites. A total of 16 ascites were prepared. The titer data of some ascites tests are shown in the following table:
[0114] Table 4: Ascites titer test data
[0115]
[0116]
[0117] 3. Antibody purification conditions exploration and test data
[0118] The above ascites was purified by 3.3% octanoic acid-thiamine precipitation method, and a total of 16 antibodies were obtained. The titer test data of some antibodies are shown in the following table:
[0119] Table 5: Purified antibody titer test data
[0120]
[0121] Ascites titer and antibody titer tests showed that the monoclonal antibodies of the 16 cell lines had good specific binding ability to the tianeptine antigen. Competition experiments with small molecule tianeptine showed good competition. Therefore, the 16 antibodies were used to test the tianeptine colloidal gold product.
[0122] Example 3 Application of monoclonal antibody anti-Tianeptine-mab1 in products
[0123] The 16 antibodies of tianeptine were verified by the immunocolloidal gold platform. The immunocolloidal gold platform is an immunochromatographic test paper, which includes a sample pad, a conjugation pad and a detection pad according to the chromatography direction. The detection pad is provided with a detection line and a quality control line. The conjugation pad is coated with a monoclonal antibody selected by colloidal gold labeling, and the detection line is coated with tianeptine hapten.
[0124] Specifically, the experimental group used 16 antibodies, 1# to 16#, obtained from the above experiment, to detect the Tianeptine standard Tianeptine of Hangzhou Anxu Biotechnology Co., Ltd. The above reagents were added, and then the results were tested using the POCT detection instrument ACG1000 (ID-A003) of Hangzhou Anxu Biotechnology Co., Ltd., and the 8# antibody was screened out as negative and with a good gradient. Some experimental data results are shown in the following table:
[0125] Table 6: Preliminary evaluation results of antibody 8#
[0126] Antibody Negative Tianeptine 200ng / ml Tianeptine 500ng / ml 1# G5 / / 6# G9 G4- G3 8# G9 G9 G3.5 13# G9- G4 G3.5+
[0127] Note: G3 to G9 represent the color depth of the test strip. The higher the value, the darker the color. + / - indicates that the color is slightly darker or lighter than this level. The lower value after adding Tianeptine, a standard substance, indicates that the small molecule has a competitive effect and the antibody can bind to Tianeptine, a standard substance.
[0128] The results showed that the gradient of antibody No. 6 was good and could be used in tianeptine products. The cut-off value reached 200ng / ml. Then the stability of antibody No. 6 was evaluated and three batches of antibody samples were prepared. The evaluation results are shown in the following table:
[0129] Table 7: Stability evaluation results of 3 batches of antibody #6
[0130] Antibody lot number Negative Tianeptine 200ng / ml Tianeptine 500ng / ml 6#-1 G9 / 9 / 9+ G3.5+ / 3.5 / 4- G3.5 / 3.5 / 3.5 6#-2 G9 / 9 G4 / 4- / 4- G3.5 / 3.5- / 3.5 6#-3 G8 / 8+ G4- / 4 G3 / 3.5- / 3.5
[0131] Antibody #6 was used to detect 750 ng / ml Tianeptine standard. The test results are shown in Table 8 and Figure 1 As shown:
[0132] Table 8: Detection results of 6# antibody against 750ng / ml Tianeptine
[0133] Antibody lot number Negative Tianeptine 750ng / ml 6# G10+ G3.5+
[0134] According to the product evaluation results, antibody No. 6 was named anti-Tianeptine-mab1, which can be used for the detection of Tianeptine antigen detection kit.
[0135] Example 4 Sequence analysis of the heavy chain V region (VH) and light chain V region (VL) of the monoclonal antibody anti-Tianeptine-mab1.
[0136] 1. Design primers for amplifying the heavy chain V region (VH) and light chain V region (VL) genes.
[0137] 2. Take the hybridoma cell line of anti-Tianeptine-mab1 in the logarithmic growth phase (about 10 7 The total RNA of the cells was extracted according to the instruction of Trizol RNA extraction kit, the first chain of cDNA was synthesized by reverse transcription using the total RNA as a template, and the VH / VL gene of the antibody was amplified by PCR using the above amplified product as a template.
[0138] 3. Recover the heavy chain VH (about 360bp) and light chain VL (about 300bp) fragments of anti-Tianeptine-mab1 and send them to the company for sequencing.
[0139] 4. Then analyze the VH / VL gene sequence:
[0140] The resulting sequence is as follows:
[0141] Nucleotide sequence of the variable region of the heavy chain: anti-Tianeptine-mab1-VH: 354 bp
[0142] CAGGTCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAGGATA
[0143] TCCTGCAAGGCTTCTGGCTACACCTTCACATCCTACTATATAGTCTGGGTGAGGCAGAGGCCTG
[0144] GACAGGGACTTGAGTGGATTGGATGGATTTATCCTGGAAATCTTAATACAAAGTACAATGAGAA
[0145] GTTCAAGGGCAAGGCCACACTGACTGCAGACAAATCCTCCAGCACAGCCTACATGCAGCTCAG
[0146] CAGCCTGACCTATGAGGACTCTGCGGTCTATTTCTGTACAAGATACTACTATGGTGCCTCCTTG
[0147] ATTACTGGGGCCAAGGCACCACTCTCACAGTAAGCAGC(SEQ ID NO.3)
[0148] The amino acid sequence of the variable region of the heavy chain: anti-Tianeptine-mab1protein: 118aa
[0149] QVQLQQSGPELVKPGASVRISCKASGYTFTSYYIVWVRQRPGQGLEWIGWIYPGNLNTKYNE KFKGKATLTADKSSSTAYMQLSSLTYEDSAVYFCTRYYYGASLDYWGQGTTLTVSS (SEQ ID NO.1) Heavy chain variable region CDR analysis, the results are shown in Table 1:
[0150] Table 1
[0151]
[0152] Variable region nucleotide sequence of light chain: anti-Tianeptine-mab1LVκ: 336 bp
[0153] AACGTGCTGATGACACAGAGCCCTCTGAGCCTGCCCGTGAGCCTGGGCGACCAAGCTAGCATCAGCTGCAGAAGCAGCCAAAACATCGTGCACAGCAACGGCAACACCTACCTGGAGTGGTACCTGCAGAAGCCCGGGCAGAGCCCTAAGCTGCTGATCTACAAGGTGAG CAACAGATTTAGCGGCGTGCCCGACAGATTCAGCGGCTCCGGCAGCGGCACCGCCTTCACCCTGAAGATCAACAGAGTGGAGGCCGAGGACCTGGGCGTGTACTACTGCTTTCAGACAAGCCACGTGCCCTACACCTTCGGCGGCGGCACCAAGCTGGAGATCAAG(SEQ ID NO.4)
[0154] The amino acid sequence of the variable region of the light chain: anti-Tianeptine-mab1LVκprotein: 112aa
[0155] NVLMTQSPLSLPVSLGDQASISCRSSQNIVHSNGNTYLEWYLQKPGQSPKLLIYKVSNRFSGV PDRFSGSGSGTAFTLKINRVEAEDLGVYYCFQTSHVPYTFGGGTKLEIK(SEQ ID NO.2)
[0156] The results of light chain variable region CDR analysis are shown in Table 2:
[0157] Table 2
[0158]
[0159] Finally, it should be noted that the above embodiments are only used to illustrate the technical solutions of the present invention, rather than to limit it. Although the present invention has been described in detail with reference to the aforementioned embodiments, those skilled in the art should understand that they can still modify the technical solutions described in the aforementioned embodiments, or replace some or all of the technical features therein with equivalents. However, these modifications or replacements do not cause the essence of the corresponding technical solutions to deviate from the scope of the technical solutions of the embodiments of the present invention.
Claims
1. An anti-tianeptine antibody or an antigen-binding fragment thereof, characterized in that: The antibody or antigen-binding fragment thereof contains the complementarity determining regions HCDR1, HCDR2 and HCDR3 of the heavy chain variable region, and the complementarity determining regions LCDR1, LCDR2 and LCDR3 of the light chain variable region; The HCDR1, HCDR2 and HCDR3 include amino acid sequences consistent with HCDR1, HCDR2 and HCDR3 of the heavy chain variable region shown in SEQ ID NO.1; the LCDR1, LCDR2 and LCDR3 include amino acid sequences consistent with LCDR1, LCDR2 and LCDR3 of the light chain variable region shown in SEQ ID NO.
2.
2. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 or LCDR3 of the anti-tianeptine antibody or antigen-binding fragment thereof is defined by any one of the Kabat, Chothia, IMGT, ABM or Contact systems or a combination of multiple definition systems; Optionally, according to the Kabat definition: the amino acid sequence of the HCDR1 is shown as SEQ ID NO.7, the amino acid sequence of the HCDR2 is shown as SEQ ID NO.12, and the amino acid sequence of the HCDR3 is shown as SEQ ID NO.15; the amino acid sequence of the LCDR1 is shown as SEQ ID NO.18, the amino acid sequence of the LCDR2 is shown as SEQ ID NO.21, and the amino acid sequence of the LCDR3 is shown as SEQ ID NO.
23.
3. The antibody or antigen-binding fragment thereof according to claim 1, characterized in that: The heavy chain variable region further comprises a framework region, and / or the light chain variable region further comprises a framework region; Optionally, the heavy chain variable region of the antibody or antigen-binding fragment thereof is as shown in SEQ ID NO.1, and the light chain variable region is as shown in SEQ ID NO.
2.
4. The antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, characterized in that: The antigen binding fragment is one of F(ab')2, Fab', Fab, Fv, scFv, dsFv, bispecific antibody and antibody minimum recognition unit; Optionally, the antibody is freed of CDR regions, and the remaining sequences are from species including one or more of mice, rats, guinea pigs, hamsters, rabbits, ferrets, cats, dogs, goats, sheep, cows, pigs, horses, monkeys and humans; Optionally, the antibody or antigen-binding fragment thereof further contains part or all of a constant region; Optionally, the constant region sequence is selected from a sequence of a partial or complete constant region of any one of IgG1, IgG2, IgG3, IgG4, IgA, IgM, IgE or IgD; Optionally, the antibody further comprises a heavy chain constant region and a light chain constant region, the light chain of the antibody is a κ chain, and the antibody is an IgG antibody.
5. Biomaterial, characterized in that The biological material is selected from any one of (i) to (iii): (i) a polynucleotide comprising a nucleotide sequence encoding the anti-tianeptine antibody or antigen-binding fragment thereof according to any one of claims 1 to 4; (ii) a vector carrying the polynucleotide described in (i). (iii) a cell, wherein the cell carries the polynucleotide described in (i), or contains the vector described in (ii), or expresses the anti-tianeptine antibody or its antigen-binding fragment; Optionally, the polynucleotide contains a fragment of the nucleotide sequence as shown in SEQ ID NO.3; Optionally, the polynucleotide contains a fragment of the nucleotide sequence shown in SEQ ID NO.
4.
6. A composition containing an antibody, characterized in that Contains the following (I) and (II) connected or separately packaged: (I) the anti-tianeptine antibody or antigen-binding fragment thereof according to any one of claims 1 to 4; (II) Label and / or solid phase carrier.
7. Use of the anti-tianeptine antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, or the biomaterial according to claim 5, or the antibody-containing composition according to claim 6 in detecting tianeptine for non-diagnostic and therapeutic purposes, or in preparing a product for detecting tianeptine.
8. A kit for detecting tianeptine, characterized in that: A composition comprising the anti-tianeptine antibody or antigen-binding fragment thereof according to any one of claims 1 to 4, or the antibody-containing composition according to claim 6.
9. The kit according to claim 8, characterized in that The kit includes a kit for immunoassay; Optionally, the kit includes an immunochromatographic detection kit, an ELISA detection kit, an immunomagnetic microparticle detection kit, an immunofluorescence detection kit or an immunoblot detection kit.
10. The kit according to claim 9, characterized in that The kit comprises an immunochromatographic test paper, wherein the immunochromatographic test paper is a competitive immunochromatographic test paper; Optionally, the detection line of the immunochromatographic test paper is coated with tianeptine hapten, and the binding pad is coated with the anti-tianeptine antibody or antigen-binding fragment thereof labeled with a marker.
Citation Information
Patent Citations
Preparing method for tianeptine molecularly imprinted electrochemical sensor
CN109324101A
Antibodies to ubiquitin c-terminal hydrolase l1 (UCH-l1) and glial fibrillary acidic protein (GFAP) and related methods
CN110366558A
Quality control product and / or calibration product for simultaneously monitoring 78 neuropsychiatric drugs
CN114739774A
Cited By
Tianeptine analogs and conjugates and use of the same in detection of tianeptine and its metabolites
WO2025221948A1
